SYDNEY--Australia-based pharmaceutical company CSL will expand its Illinois manufacturing facility under a previously announced $1.5 billion move to increase U.S. production. CSL, which produces ...

CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art ...

CSL’s new Illinois investment adds to over $3B spent on U.S. operations since 2018. The expansion will create at least 300 ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

CSL, a global pharmaceutical manufacturer based in Melbourne, Australia, has broken ground on a $1.5 billion expansion of its campus in Kankakee, roughly 60 miles southwest of Chicago. The company has ...

CSL Behring setzt auf dynamische Prozesssimulation gekoppelt mit Live-Produktionsdaten für robustere Abläufe und höhere ...

Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...

The firm promises to produce millions of vaccine doses to in the case of an influenza pandemic.

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

The news: CSL has committed to a USD1.5 billion ($2.12 billion) expansion of its Illinois plasma therapy manufacturing facility, which it broke ground on Monday. The numbers: The Kankakee facility ...